Guidance for the use of buprenorphine and buprenorphine with naloxone for the treatment of opioid dependence in NHS Grampian

Size: px
Start display at page:

Download "Guidance for the use of buprenorphine and buprenorphine with naloxone for the treatment of opioid dependence in NHS Grampian"

Transcription

1

2 Title: Unique Identifier: Replaces: Guidance for the use of buprenorphine and buprenorphine with naloxone for the treatment of opioid dependence in NHS Grampian NHSG/guid/bup/MGPG733 NHSG/prot/bup/MGPG518 Across NHS Boards Organisation Wide Directorate Clinical Service Sub Department Area Yes This controlled document shall not be copied in part or whole without the express permission of the author or the author s representative. Lead Author/Co-ordinator: Subject (as per document registration categories): Key word(s): Process Document: Policy, Protocol, Procedure or Guideline Document application: Purpose/description: Specialist Pharmacists in Substance Misuse Clinical Guidance Guidance, buprenorphine, naloxone, suboxone, subutex, opioid, dependence, OST Guidance NHS Grampian This guidance advises all staff, involved in prescribing for substance misuse patients, on the appropriate use of buprenorphine products in managing opioid dependence. Responsibilities for implementation: Organisational: Departmental: Area: Policy statement: Review: Management Teams Substance misuse management team General practitioner practices It is the responsibility of all staff to ensure that they are working to the most up to date and relevant policies, protocols procedures. This guidance will be reviewed in two years or sooner if current treatment recommendations change. UNCONTROLLED WHEN PRINTED Review Date: April 2017 Identifier: NHSG/guid/bup/MGPG733 - i -

3 This document is also available in large print and other formats and languages, upon request. Please call NHS Grampian Corporate Communications on (01224) or (01224) Responsibilities for review of this document: Responsibilities for ensuring registration of this document on the NHS Grampian Information/ Document Silo: Physical location of the original of this document: Job/group title of those who have control over this document: Responsibilities for disseminating document as per distribution list: Substance Misuse Pharmacists Pharmacy and Medicines Directorate Substance Misuse Pharmacist Office, Fulton Clinic Specialist Pharmacists in Substance Misuse Substance Misuse Pharmacists Revision History: Revision Date Previous Revision Date Summary of Changes (Descriptive summary of the changes made) Changes Marked* (Identify page numbers and section heading ) July 2014 July 2012 Transferred to new template. Whole document July 2014 July 2012 Removed reference to specific types of opioid receptors. Page 2, Section 2 July 2014 July 2012 Condensed 3.1 and 3.2 removing repetition. July 2014 July 2012 Removed Section 4. Suboxone now preferred over buprenorphine as a sole agent in pregnancy. July 2014 July 2012 Removed recommendation regarding suitability over methadone with enzyme enducers/inhibitors SPC amended to reflect potential for interaction. July 2014 July 2012 Removed duplication of maximum dose. Page3, Section 3.1 Page 3, Section 4 (Removed) Page 3,Section 4 Page 5, Section 5.10 UNCONTROLLED WHEN PRINTED Review Date: April 2017 Identifier: NHSG/guid/bup/MGPG733 - ii -

4 Revision Date Previous Revision Date Summary of Changes (Descriptive summary of the changes made) July 2014 July 2012 Removed repetition of partial agonistic effect. July 2014 July 2012 Amended naming of branded product to read near patient testing. July 2014 July 2012 Removed statement regarding more thorough review every 3 months. Current practice is for regular review dependent on patient progress. July 2014 July 2012 Clarified information on rate of reduction. July 2014 July 2012 Information regarding withdrawal on discontinuation moved forward in document. July 2014 July 2012 Removed information regarding pharmacies providing supervision of buprenorphine products. Majority of pharmacies who dispense methadone will also dispense buprenorphine. July 2014 July 2012 Removed information regarding Suboxone being contraindicated in pregnancy July 2014 July 2012 Amended advice regarding use in pregnancy as per changes to Suboxone SPC. July 2014 July 2012 Amended advice in breastfeeding section to reflect above change. July 2014 July 2012 Removed section regarding DVLA as this is not restricted to prescribing buprenorphine but more widely. December July 2012 Added estimated to 2014 calculation of opioid load. December July 2012 Added statements clinical 2014 appropriateness of buprenorphine vs methadone December 2014 July 2012 and patient choice. Reworded sections 5.1. and 5.3. Changes Marked* (Identify page numbers and section heading ) Page 5, Section 6.3 Page 5, Section 6.3 Page 6, Section 6.4 Page 6, Section 7.1 Page 6, Section 7.2 Page 7, Section 8.3 Page 7, Section 11 Page 7, Section 11.1 Page 7, Section Page 9. Section 11.6 in previous document Page 3, Section 4.1 Page 3, Sections 4 Page 3-4, Sections 5.1 and 5.3 UNCONTROLLED WHEN PRINTED Review Date: April 2017 Identifier: NHSG/guid/bup/MGPG733 - iii -

5 Revision Date December 2014 December 2014 December 2014 Previous Revision Date July 2012 Summary of Changes (Descriptive summary of the changes made) Added statement regarding requirement for day 2 dosing during titration. Changes Marked* (Identify page numbers and section heading ) Page 5, Section 5.11 July 2012 Reworded section 6.3. Page 5, Section 6.3 July 2012 Added information on supervision for people previously on take home methadone. March 2015 July 2012 Added new doses of generic buprenorphine. April 2015 July 2012 Added info on receptor occupancy. Amended precipitated withdrawal to read symptoms of withdrawal. April 2015 July 2012 Added line re weighing up risks of illicit use vs risks of prescribing. April 2015 July 2012 Removed information regarding administration every 2/3 days. Not used in practice. Page 7, Section 8.2 Page 4, Section 5.6 Page 2, Section 2 Page 4, Section 5.4 Page 5,Section 5 April 2015 July 2012 Added section on missed Page 7, Section 9. doses. April 2015 July 2012 Change to Guidance from Throughout Protocol. May 2015 July 2012 Addition of electronic link. Page 6, Section 7.4 May 2015 July 2012 Precautions moved below CI. Page 7, Section 10. May 2015 July 2012 Addition of electronic link. Section 11, page 8 * Changes marked should detail the section(s) of the document that have been amended i.e. page number and section heading. UNCONTROLLED WHEN PRINTED Review Date: April 2017 Identifier: NHSG/guid/bup/MGPG733 - iv -

6 Guidance For The Use Of Buprenorphine And Buprenorphine With Naloxone For the Treatment of Opioid Dependence in NHS Grampian Contents Page No 1 Introduction Pharmacology Key Recommendations Which Patients May Be Considered Suitable For Treatment With A Buprenorphine Product? Initiation Of Therapy Maintenance Dosage Reduction Supervision Of Consumption Missed Doses Contraindications To Use Of Buprenorphine Containing Products Precautions For Buprenorphine Containing Products... 7 See Section Side Effects Consultation References Sources Used To Provide The Information For This Document:... 9 UNCONTROLLED WHEN PRINTED Review Date: April 2017 Identifier: NHSG/guid/bup/MGPG

7 Guidance For The Use Of Buprenorphine And Buprenorphine With Naloxone For The Treatment Of Opioid Dependence in NHS Grampian 1 Introduction This guidance applies to both buprenorphine with naloxone (Suboxone sublingual tablets) and buprenorphine (Subutex and generic sublingual tablets are available). Suboxone is currently the recommended product for use in Grampian. This document is designed as a guide to the use of buprenorphine products in the treatment of opioid dependency and is intended for use by all clinicians and health care professionals involved in the treatment of this patient group in Grampian. Treatment must only be commenced by or on the recommendation of a specialist clinician in substance misuse. This may include GPs with the appropriate knowledge and/or training. 2 Pharmacology Buprenorphine is a partial opioid agonist which produces a milder, less euphoric and less sedating effect than full opioid agonists such as heroin, morphine and methadone. Nevertheless, its activity is usually sufficient to diminish cravings for heroin, and prevent or alleviate opioid withdrawal in dependent heroin users. Buprenorphine exerts little effect when swallowed and thus is administered via the sublingual route. Buprenorphine can block the effects of other opioid drugs, both illicit and prescribed. Patients should be informed of this when discussing buprenorphine as a treatment choice. Clinicians should be aware of this where opioid pain relief is required. This may be an issue during both planned and emergency admissions to hospital. As it is a partial opioid agonist, a ceiling effect is exhibited where continued dose increases will not result in a proportionate increase in effect. This means that buprenorphine has a lower risk of overdose than full agonists if taken as prescribed. Overdose remains a risk with poly drug use. Studies have shown that, in most patients, little additional effect is gained at doses above 16mg. [1] At this dose, approximately 95% of receptors are occupied leaving little room for additional effect. Suboxone includes the opioid antagonist naloxone in a combined sublingual tablet. If injected, naloxone has a high bioavailability and is liable to result in symptoms of withdrawal in opioid dependent patients. When taken sublingually, as prescribed, naloxone has very low bioavailability and does not diminish the therapeutic effect of the buprenorphine. Therefore theoretically, Suboxone should be subject to less misuse than buprenorphine as a sole agent. UNCONTROLLED WHEN PRINTED Review Date: April 2017 Identifier: NHSG/guid/bup/MGPG

8 3 Key Recommendations 3.1 UK guidance [2] recommends that, following assessment of the patient and where both methadone and buprenorphine containing products are deemed equally suitable, methadone should be prescribed as first choice. An exception to this may include patients who express a strong preference towards buprenorphine, where it is clinically appropriate and the patient is informed of all available treatment options. 3.2 Buprenorphine containing products are recommended for substitution treatment for opioid drug dependence within a framework of medical, social and psychological treatment. 3.3 Where a buprenorphine containing product is the appropriate choice for maintenance treatment and where there are no contraindications to its use, Suboxone should be prescribed in preference to buprenorphine as a sole agent. 4 Which Patients May Be Considered Suitable For Treatment With A Buprenorphine Product? 4.1 Patients currently consuming a total daily opioid dose estimated to be the equivalent to 30mg or less of methadone. Illicit opioids should be included in this calculation. 4.2 Opioid drug users for whom methadone treatment is deemed less appropriate, e.g. in QTc prolongation. 4.3 Opioid drug users for whom methadone treatment is no longer working, e.g. for those who struggle on a reducing methadone dose. Metabolism varies between individuals but many find that at lower doses of methadone the dose may not hold them for the full 24 hours. Buprenorphine has a longer half life and is not as prone to the same issue which may make dose reductions easier to tolerate. 4.4 Patients who are considered suitable candidates for a detoxification programme. 4.5 Younger patients (between 16 and 18 years) due to the decreased risk of overdose (see Section 11.4). 4.6 Patients whose alcohol and/or poly drug use puts them at increased risk of overdose. 5 Initiation Of Therapy 5.1 Opioid dependence must be diagnosed prior to commencing treatment. In patients who are not currently receiving methadone maintenance treatment, a comprehensive assessment should be undertaken which includes a minimum of 2 confirmatory supervised screens (urine or oral fluid). 5.2 Patients must be assessed on an individual basis by a specialist clinician in substance misuse to determine suitability of treatment. Where the specialist service UNCONTROLLED WHEN PRINTED Review Date: April 2017 Identifier: NHSG/guid/bup/MGPG

9 has initiated treatment, care may be transferred to primary care on the agreement of all parties involved. (Specialist clinician, primary care clinician and patient). 5.3 A discussion of the available treatment options should be undertaken. Corporate patient information leaflets and a flip chart are available to support discussion with further patient information leaflets on buprenorphine for treatment of opioid dependence are available from This may be useful for some patients but issues with literacy should be considered. 5.4 Patients who are positive for viral hepatitis, on concomitant medicinal products which may interact with buprenorphine and/or have existing liver dysfunction are at risk of accelerated liver injury. Regular monitoring of liver function is recommended in these patients. As the pharmacokinetics of buprenorphine containing products may be altered in patients with hepatic impairment, lower initial doses and careful dose titration in patients with mild to moderate hepatic impairment are recommended. Buprenorphine containing products are contraindicated in [4] [5] patients with severe hepatic dysfunction/impairment. Both methadone and buprenorphine can accumulate in patients with hepatic impairment. Clinicians should weigh up the risk of continued illicit drug use versus the risks associated with the prescribed drug. With its ceiling effect, buprenorphine may present less of a risk of over sedation and overdose. 5.5 Precipitated withdrawal may occur when buprenorphine is first administered to an opioid dependent patient due to its high affinity for opioid receptors. Buprenorphine displaces other opioids from the receptors but exhibits less intrinsic activity thus inducing symptoms of withdrawal. Precipitated withdrawal typically occurs within 1 to 3 hours after the first buprenorphine dose and peaks within 3 to 6 hours before subsiding. This should be discussed with all patients prior to commencing treatment with buprenorphine containing substances and they should be reassured that, should they experience precipitated withdrawal, symptoms will subside. In order to minimise the risk of precipitated withdrawal, the first dose of buprenorphine containing product should not be given until the patient has been assessed and displays signs of opioid withdrawal. This should be a minimum of 12 hours after last heroin use and 24 hours after last methadone use. Where the patient is already experiencing mild symptoms of withdrawal the first dose of Suboxone should give them some relief and they are more likely to continue with this treatment. 5.6 Suboxone is available as 2mg (2mg buprenorphine and 500micrograms naloxone) and 8mg (8mg buprenorphine and 2mg naloxone) sublingual tablets. Buprenorphine as a sole agent is available as 400micrograms, 1mg, 2mg, 4mg, 6mg and 8mg sublingual tablets. Clinicians should advise patients that the sublingual route is the only effective and safe route of administration for this drug. The active ingredient will generally be absorbed after 3-5 minutes however pulp may be present for minutes after administration but will contain little buprenorphine. UNCONTROLLED WHEN PRINTED Review Date: April 2017 Identifier: NHSG/guid/bup/MGPG

10 5.7 It is recommended that the administration of initial doses are supervised (see Section 8). The clinician should discuss intial dosage instructions with both the patient and the community pharmacist to ensure clarity in the details of the initial dosing regimen. 5.8 An initial dose of 4mg of buprenorphine which should be followed by a further dose of 4mg later on the same day if there is no precipitated withdrawal. A minimum gap of 3 hours is recommended before consuming the second dose to allow sufficient time for appearance of precipitated withdrawal should it occur. Where precipitated withdrawal occurs, the second dose should be delayed until symptoms of withdrawal begin to reduce. 5.9 The dose should be titrated according to patient response as per Table 1 below It is recommended that patients are seen prior to each dosage increase to monitor efficacy and establish whether further dose increases are required. Table 1 Dose expressed as mg buprenorphine Day 1 4mg followed by a further 4mg after minimum 3 hours (Section 5.8) Day 2* 8mg Day 3 or next Daily dose increased to 16mg if required appointment 5.11 *Patient may be increased to 16mg on Day 2 where clinically appropriate to do so according to patient response. The majority of patients will gain minimal additional benefit at doses above 16mg (Section 2) however doses of up to 24mg Suboxone are licensed When converting from methadone, the patient s total daily opioid load should be 30mg of methadone per day or lower. Higher doses may lead to precipitated withdrawal (see Section 5.5) or treatment failure in circumstances where buprenorphine is not strong enough to cover withdrawal symptoms from cessation of full agonist opioids. Illicit opioid use should be considered, and accounted for, when calculating a patient s total daily opioid load. 6 Maintenance 6.1 The effective maintenance dose of buprenorphine products will be up to 16mg in most patients. [1][3] Very occasionally doses up to 24mg may be required (the maximum licensed dose for Suboxone ). 6.2 Patients should be seen a minimum of once a fortnight initially and which may be extended to a minimum of once a month with positive progress. 6.3 Urine or oral fluid tests for drugs of misuse should be undertaken a minimum of four times a year as determined by the clinician and according to each individual patient s progress. Presence of an illicit drug in a sample should be used to guide treatment. NB: In Grampian, current laboratory urine screening does not identify UNCONTROLLED WHEN PRINTED Review Date: April 2017 Identifier: NHSG/guid/bup/MGPG

11 buprenorphine (March 2015). Near patient testing, where available, may identify buprenorphine. 6.4 Co-existing physical, emotional social and legal problems as well as drug and alcohol misuse should be addressed. 3 rd sector agencies may be able to provide this additional support and patients should be signposted or referred accordingly. 7 Dosage Reduction 7.1 Once the buprenorphine dose is stabilised, or a patient has been maintained on buprenorphine the following may be used as an approximate guide to reducing dose. Although the reduction rate is presented as every 1 to 2 weeks in literature, patient response and ability to cope/continue with the reduction is key. If the patient begins to struggle with the rate of reduction, it should be halted and the patient stabilised on a dose where they feel comfortable until ready to continue. 7.2 Patients tend to experience withdrawal symptoms at the end of treatment irrespective of the length of detoxification and should be advised and supported accordingly. Table 2 [3] Daily buprenorphine dose Above 16mg 8mg to 16mg 2mg to 8mg Below 2mg Reduction rate 4mg every 1 to 2 weeks 2mg to 4mg every 1 to 2 weeks 2mg every 1 to 2 weeks micrograms every 1 to 2 weeks 7.3 For detoxification regimens, more rapid reductions may be considered and can be achieved within a one to two week timeframe. Rapid reductions are only recommended for use by specialist clinicians in substance misuse and are not recommended in primary care settings. 7.4 A discussion with the patient around the feasibility of naltrexone post reduction may be introduced at this time. See NHS Grampian guidance. 8 Supervision Of Consumption 8.1 As a minimum, it is recommended that doses of buprenorphine containing products should be supervised whilst titrating and stabilising the dose. This will provide the patient with additional support and monitoring from the community pharmacist and ensure that prescribing is appropriate. Where patients are new to treatment with an opioid substitute, current recommendations [6] state that initial doses should be prescribed daily with consumption supervised by a community pharmacy for at least the first three months of treatment. After this point, relaxation of supervised consumption may be considered on an individual patient basis at the discretion of the prescriber. Relaxation of supervision may be considered appropriate where the patient is deemed to be stable and can demonstrate continued abstinence from illicit drug use and compliance with treatment. UNCONTROLLED WHEN PRINTED Review Date: April 2017 Identifier: NHSG/guid/bup/MGPG

12 8.2 Where patients have previously been maintained on a take home methadone prescription and are switching to a buprenorphine product, a short period of supervision during the titration will allow better monitoring and support of the patient s response to the change in medication. 8.3 For those patients on maintenance regimens, it is recommended that each instalment consists of no more than one week supply of buprenorphine to minimise the risk of large quantities being diverted. Twice or three times a week dispensing should be prescribed as a first step. 9 Missed Doses If a patient misses 3 or more doses of a buprenorphine product it is advised that the clinician discuss with the patient what has happened during this period. If 3 or more doses have been missed, the patient should be re-titrated as described in Section 5. If they have taken any opioid drugs in the interim, precipitated withdrawal will be a risk when restarting medication. They should be advised to wait 12 hours for heroin or 24 hours for methadone and be feeling mild symptoms of withdrawal before taking the next dose of buprenorphine. 10 Contraindications To Use Of Buprenorphine Containing Products A full list of contraindications can be found in the Summary of product characteristics or the British National Formulary. i. Patient must be 16 years of age or over for Subutex, over 15 years for Suboxone and have no other contraindications. ii. Severe respiratory insufficiency. iii. Severe hepatic insufficiency. iv. Acute alcoholism or delirium tremens. v. Hypersensitivity to buprenorphine, naloxone or to any of the excipients. vi. Patients suffering chronic pain for which additional opioid analgesia is frequently required. 11 Precautions For Buprenorphine Containing Products 11.1 Pregnancy Specialist advice should be sought when treating this patient group. Methadone remains first line where initiating an opioid substitution therapy in pregnancy. Where methadone is not the preferred treatment option, a buprenorphine product may be considered if the benefits of prescribing outweigh perceived risk. Where a buprenorphine product is indicated, Suboxone should be prescribed in preference due to the decreased risk of misuse Breastfeeding For mothers stabilised on a buprenorphine product who wish to breastfeed, an individual risk-benefit analysis to inform decision making should be undertaken. Due UNCONTROLLED WHEN PRINTED Review Date: April 2017 Identifier: NHSG/guid/bup/MGPG

13 to the lack of evidence of the effects of these drugs on breastfed infants, manufacturers advice is to avoid, although expert consensus opinion states that the effects of these medications on the breastfed infants is likely to be minimal and that breastfeeding is not contraindicated. [7] 11.3 Liver function See Section Overdose Buprenorphine is reported to be safer in overdose than full agonists, such as methadone [3], causing less respiratory depression. This being said, drug related deaths involving buprenorphine have been reported particularly when taken in combination with other sedative drugs such as alcohol or benzodiazepines. In the event of accidental overdose, medical advice should be sought. Standard procedures for reversing opioid-induced respiratory depression should be followed. [4][5] Naloxone should be initiated titrating upwards until adequate respiratory ventilation is achieved. It may be necessary to use more than the normal amount of naloxone. General supportive measures should be instituted including close monitoring of respiratory and cardiac status. If the patient vomits care must be taken to prevent aspiration of the vomitus. Further guidance can be found in the document Patient Group Direction For The Administration Of Naloxone Injection In Suspected Opioid Overdose For Patients Aged 12 Years And Over By Nurses And Midwives Working Within NHS Grampian available on the NHS Grampian intranet Concomitant use of CNS depressants As with methadone, concomitant use of buprenorphine with benzodiazepines, alcohol and other CNS depressant drugs may result in fatal overdose. Caution should be employed when initiating buprenorphine containing products in poly drug users. Consideration should be given to the potential illicit use of CNS depressants before initiating treatment. 12 Side Effects A full list of side effects and cautions can be found in the Summary of product characteristics or the British National Formulary. The most common side effects of buprenorphine containing products include: constipation, headaches, sleeplessness, sickness and sweating. It should be noted that patients often report a clear head with buprenorphine containing products as opposed to the clouding effect often experienced with methadone or heroin. UNCONTROLLED WHEN PRINTED Review Date: April 2017 Identifier: NHSG/guid/bup/MGPG

14 13 Consultation The document was sent to the following individuals/groups for consultation: Steve Beason Psychiatrist, NHSG Substance Misuse Service Carol Buchanan GP with Special Interest in Substance Misuse Lynne Crighton Specialist Pharmacist, Gastroenterology Bruce Davidson Consultant Psychiatrist, Clinical Lead NHSG Substance Misuse Service Richard Legg GP with Special Interest in Substance Misuse Stephen Lynch GP, Calsayseat Medical Group Alison Mearns GP with Special Interest in Substance Misuse Isobel Morison Specialist Pharmacist, Aberdeen Maternity Hospital Allen Robertson Quality Assurance Supervisor, NHSG Substance Misuse Service Lucy Skea Specialist Pharmacist in Substance Misuse CPN Clinical Leads NHSG Substance Misuse Service CPN Team Leads NHSG Substance Misuse Service Medical Team NHSG Substance Misuse Service NHS Grampian Mental Health Operational Medicines Management Group 14 References Sources Used To Provide The Information For This Document: [1] Greenwald MK, Johanson CE, Moody DE, Woods JH, Kilbourn MR, Koeppe RA, et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology. 2003; 28: [2] National Institute of Clinical Excellence. Methadone and buprenorphine for the management of opioid dependence. London: NICE technology appraisal guidance 114. January Cited 15/07/2014 [3].Ford, C. Halliday, K. Lawson, E. Browne, E. et al. Guidance for the use of substitute prescribing in the treatment of opioid dependence in primary care. London: January Cited 15/07/ [4] Reckitt Benckiser Pharmaceuticals. Summary of Product Characteristics: Suboxone. Slough, UK. Cited 15/07/ [5] Reckitt Benckiser Pharmaceuticals. Summary of Product Characteristics: Subutex. Slough, UK. Cited 15/07/ [6] Department of Health (England) and the devolved administrations (2007). Drug Misuse and Dependence: UK Guidelines on Clinical Management. London: Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Ireland Executive. Cited 15/07/2014. [7] Whittaker, A. The Essential Guide to Problem Substance Use During Pregnancy. A Resource Book for Professionals. London: DrugScope. Updated edition UNCONTROLLED WHEN PRINTED Review Date: April 2017 Identifier: NHSG/guid/bup/MGPG

Guidance For The Use Of Naltrexone In The Maintenance Of Abstinence in Formerly Opioid Dependent Adults By Clinicians Working Within NHS Grampian

Guidance For The Use Of Naltrexone In The Maintenance Of Abstinence in Formerly Opioid Dependent Adults By Clinicians Working Within NHS Grampian Title: Identifier: Guidance For The Use Of Naltrexone In The Maintenance Of Abstinence in Formerly Opioid Dependent Adults By Clinicians Working Within NHS Grampian NHSG/Guide/NHSG_NaltexMA_885 Replaces:

More information

Guidance For The Use Of Lofexidine In The Symptomatic Management Of Opioid Withdrawal By Clinicians Working Within NHS Grampian. Consultation Group:

Guidance For The Use Of Lofexidine In The Symptomatic Management Of Opioid Withdrawal By Clinicians Working Within NHS Grampian. Consultation Group: NHS...Ness Grampian Guidance For The Use Of Lofexidine In The Symptomatic Management Of Opioid Withdrawal By Clinicians Working Within NHS Grampian Co-ordinators: Specialist Pharmacists in Substance Misuse

More information

Substitution Therapy for Opioid Use Disorder The Role of Suboxone

Substitution Therapy for Opioid Use Disorder The Role of Suboxone Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM

More information

Guidance For NHS Grampian Clinicians On The Management Of Insomnia And The Use Of Hypnotics

Guidance For NHS Grampian Clinicians On The Management Of Insomnia And The Use Of Hypnotics Guidance For NHS Grampian Clinicians On The Management Of Insomnia And The Use Of Hypnotics Co-ordinators: Specialist Pharmacists in Substance Misuse Reviewer: Bruce Davidson Consultant Psychiatrist and

More information

SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program

SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets Risk Evaluation and Mitigation Strategy (REMS) Program Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Prescribers

More information

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance

More information

Drug Misuse and Dependence Guidelines on Clinical Management

Drug Misuse and Dependence Guidelines on Clinical Management Department of Health Scottish Office Department of Health Welsh Office Department of Health and Social Services, Northern Ireland Drug Misuse and Dependence Guidelines on Clinical Management An Executive

More information

GUIDELINES FOR THE MANAGEMENT OF PALLIATIVE CARE PATIENTS WITH A HISTORY OF SUBSTANCE MISUSE

GUIDELINES FOR THE MANAGEMENT OF PALLIATIVE CARE PATIENTS WITH A HISTORY OF SUBSTANCE MISUSE GUIDELINES FOR THE MANAGEMENT OF PALLIATIVE CARE PATIENTS WITH A HISTORY OF SUBSTANCE MISUSE 41.1 GENERAL PRINCIPLES The ICD 10 diagnostic criteria for dependency syndrome are listed in Table 41.1 below.

More information

NHS Grampian Protocol For The Prescribing And Administration Of Oral Opioids Following Trauma Or Surgery

NHS Grampian Protocol For The Prescribing And Administration Of Oral Opioids Following Trauma Or Surgery Acute Sector NHS Grampian Protocol For The Prescribing And Administration Of Oral Opioids Following Trauma Or Surgery Co-ordinators: Dr Karen Cranfield, Consultant Anaesthetist, Lead Acute Pain Sector

More information

Prescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence)

Prescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence) Hull & East Riding Prescribing Committee Prescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence) Patients Name: Unit Number: Patients Address:.. G.P s Name:.. Communication We agree

More information

NHS Grampian Protocol For The Prescribing And Administration Of Oral Opioids Following Trauma Or Surgery in Adults. Consultation Group: See Page 5

NHS Grampian Protocol For The Prescribing And Administration Of Oral Opioids Following Trauma Or Surgery in Adults. Consultation Group: See Page 5 NHS...... Grampian Acute Sector NHS Grampian Protocol For The Prescribing And Administration Of Oral Opioids Following Trauma Or Surgery in Adults Co-ordinators: Consultant Anaesthetist, Lead Acute Pain

More information

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION Naltrexone is used as part of a comprehensive programme of treatment against alcoholism to reduce the

More information

Consultation Group: Dr Amalia Mayo, Paediatric Consultant. Review Date: March Uncontrolled when printed. Version 2. Executive Sign-Off

Consultation Group: Dr Amalia Mayo, Paediatric Consultant. Review Date: March Uncontrolled when printed. Version 2. Executive Sign-Off Policy For The Adjustment Of Insulin Injections By Paediatric Diabetes Specialist Nurses/Community Paediatric Nurses Diabetes Working With Children Within NHS Grampian Co-ordinators: Lead Paediatric Diabetes

More information

LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE

LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE DR. SHILPA ADARKAR ASSOCIATE PROFESSOR DEPARTMENT OF PSYCHIATRY & DRUG DEADDICTION CENTRE OF EXCELLENCE SETH GSMC & KEMH LONG TERM OPTIONS FULL AGONIST PARTIAL

More information

The safety concerns defined with the reference product apply to Buprenorphine-Naloxone 2/0.5 mg, 8/2 mg, sublingual tablets.

The safety concerns defined with the reference product apply to Buprenorphine-Naloxone 2/0.5 mg, 8/2 mg, sublingual tablets. These products are indicated in the substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter

More information

Now available. A maintenance dose of SUBOXONE mg once daily is clinically effective for most patients*1. Once-daily dosing in a single tablet

Now available. A maintenance dose of SUBOXONE mg once daily is clinically effective for most patients*1. Once-daily dosing in a single tablet Now available SUBOXONE Once-daily dosing1 12 mg and 16 mg tablets A maintenance dose of SUBOXONE 12-16 mg once daily is clinically effective for most patients*1 Effective maintenance dosing with SUBOXONE

More information

Guidance for naltrexone prescribing

Guidance for naltrexone prescribing Document level: Drug Alcohol (Trustwide) Code: DA7 Issue number: 2 Guidance for naltrexone prescribing Lead executive Authors details Type of document Target audience Document purpose Lead Clinical Director

More information

Medicines Optimisation Strategy

Medicines Optimisation Strategy Clinical Reducing Dosing Errors with Opioid Medicines (Controlled Drug SOP): Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic

More information

Service Level Agreement for the Provision of Level 1 Substance Misuse Services from a Community Pharmacy under contract to NHS Grampian

Service Level Agreement for the Provision of Level 1 Substance Misuse Services from a Community Pharmacy under contract to NHS Grampian Service Level Agreement for the Provision of Level 1 Substance Misuse Services from a Community Pharmacy under contract to NHS Grampian 1. Introduction The provision of Substance Misuse (SM) services through

More information

Guidance For The Detoxification Of Alcohol Dependent Patients In Community Or Outpatient Settings

Guidance For The Detoxification Of Alcohol Dependent Patients In Community Or Outpatient Settings Guidance For The Detoxification Of Alcohol Dependent Patients In Community Or Outpatient Settings Co-ordinators: Fiona Raeburn, Specialist Pharmacist in Substance Misuse Reviewer: Dr Seonaid Anderson,

More information

Dr Alistair Dunn. General Practitioner Whangarei

Dr Alistair Dunn. General Practitioner Whangarei Dr Alistair Dunn General Practitioner Whangarei 1982 Temgesic = Buprenorphine Sublingual opiate analgesic 0.2 mg Popular drug of abuse 1991 Temgesic NX = Bup & Nalxone Nalxone added to deter abuse 1999

More information

PALLIATIVE CARE PRESCRIBING FOR PATIENTS WHO ARE SUBSTANCE MISUSERS

PALLIATIVE CARE PRESCRIBING FOR PATIENTS WHO ARE SUBSTANCE MISUSERS PALLIATIVE CARE PRESCRIBING FOR PATIENTS WHO ARE SUBSTANCE MISUSERS Background information Substance misusers who develop palliative care needs are likely to have psychological, social and existential

More information

Buprenorphine pharmacology

Buprenorphine pharmacology Buprenorphine pharmacology Victorian Opioid Management ECHO Department of Addiction Medicine St Vincent s Hospital Melbourne 2018 Page 1 Opioids full, partial, antagonist Full Agonists - bind completely

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Drug Misuse: opiate detoxification of drug misusers in the community, hospital and prison. 1.1 Short title Drug misuse detoxification

More information

This letter authorises the extended use of the following guidance until 1st June 2019:

This letter authorises the extended use of the following guidance until 1st June 2019: NHS Grampian Westholme Woodend Hospital Queens Road ABERDEEN AB15 6LS NHS Grampian Date: 13Th November 2018 Our Ref: FA_ONS_Guide/MGPG/Nov18 Enquiries to: Frances Adamson Extension: 56689 Direct Line:

More information

Buprenorphine treatment

Buprenorphine treatment South London and Maudsley NHS Foundation Trust Buprenorphine treatment Information for service users Page Buprenorphine treatment What is buprenorphine? Buprenorphine (trade name Subutex ) is an opioid

More information

Talking with your doctor

Talking with your doctor SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) Talking with your doctor Opioid dependence can be treated. Talking with your healthcare team keeps them aware of your situation so they may

More information

Treatment of drug dependence What you need to know

Treatment of drug dependence What you need to know Treatment of drug dependence What you need to know Opioid Replacement Therapy for heroin and opioid dependence Information for family members and significant others Contents What help is there for family

More information

Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04

Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Date issued Issue 1 Nov 2018 Planned review Nov 2021 PPT-PGN 18 part of NTW(C)38 Pharmaceutical

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Drug Misuse: opiate detoxification of drug misusers in the community, hospital and prison. 1.1 Short title Drug misuse detoxification

More information

1.1. This guideline applies to medical, nursing and pharmacy staff in the safe and appropriate prescription and administration of acamprosate.

1.1. This guideline applies to medical, nursing and pharmacy staff in the safe and appropriate prescription and administration of acamprosate. SHARED CARE GUIDELINE FOR ACAMPROSATE 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical, nursing and pharmacy staff in the safe and appropriate prescription and administration of

More information

Opioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine

Opioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine Natural derivatives of opium poppy - Opium - Morphine - Codeine Opioid Agonists Semi synthetics: Derived from chemicals in opium -Diacetylmorphine Heroin - Hydromorphone Synthetics - Oxycodone Propoxyphene

More information

Guidelines for Community Detoxification using Buprenorphine.

Guidelines for Community Detoxification using Buprenorphine. Subject Title NHS Fife Community Health Partnerships Addiction Services Guidelines for Community Detoxification using Buprenorphine. Intranet Procedure No A3 Author Dr A Baldacchino Copy No 3 Reviewer

More information

Module Two: Pharmacotherapies for Opioid Substitution Treatment

Module Two: Pharmacotherapies for Opioid Substitution Treatment Module Two: Pharmacotherapies for Opioid Substitution Treatment Neurobiology of Addiction Pharmacology of Opioids Methadone Buprenorphine Pharmacokinetics of Methadone & Buprenorphine Opioid effects Intoxication

More information

1.4 The CADAS teams do not provide a service for residents of Bournemouth or Poole.

1.4 The CADAS teams do not provide a service for residents of Bournemouth or Poole. Pan Dorset Prescribing Protocol 1- Introduction 1.1 This policy provides guidance in relation to the Community Alcohol and Drug Service (CADAS). The service offers pharmacological interventions alongside

More information

Medical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center

Medical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Medical Assisted Treatment Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Current Trends Prescription Drug Abuse/Addiction Non-medical use of prescription pain killers

More information

PATIENT GROUP DIRECTION (PGD)

PATIENT GROUP DIRECTION (PGD) PATIENT GROUP DIRECTION (PGD) SUPPLY OF NALOXONE HYDROCHLORIDE INJECTION BY REGISTERED NURSES TO CLIENTS BEING RELEASED FROM HMP FORD Version Number: 01HMP Patient Group Direction originally drawn up by:

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Methadone and buprenorphine for the management of opioid dependence

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Methadone and buprenorphine for the management of opioid dependence NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Appraisal Methadone and buprenorphine for the management of opioid dependence Comments received from Consultees and Commentators on the draft scope

More information

Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of Opioid Dependence Abbreviated Version

Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of Opioid Dependence Abbreviated Version Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of Opioid Dependence Abbreviated Version Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of

More information

Safe Prescribing of Drugs with Potential for Misuse/Diversion

Safe Prescribing of Drugs with Potential for Misuse/Diversion College of Physicians and Surgeons of British Columbia Safe Prescribing of Drugs with Potential for Misuse/Diversion Preamble This document establishes both professional standards as well as guidelines

More information

BNSSG Shared Care Guidance Please complete all sections

BNSSG Shared Care Guidance Please complete all sections NHS Bristol CCG NHS North Somerset CCG NHS South Gloucestershire CCG North Bristol NHS Trust University Hospitals Bristol NHS Foundation Trust Weston Area Health NHS Trust BNSSG Shared Care Guidance Please

More information

Questions & Answers About Probuphine. Here are the answers to some questions you may have about the Probuphine implant:

Questions & Answers About Probuphine. Here are the answers to some questions you may have about the Probuphine implant: Questions & Answers About Probuphine Here are the answers to some questions you may have about the Probuphine implant: 1. Can my doctor prescribe and insert Probuphine? 2. What should I do after the Probuphine

More information

The doctor/nmp who prescribes the medication legally assumes clinical responsibility for the drug and the consequences of its use.

The doctor/nmp who prescribes the medication legally assumes clinical responsibility for the drug and the consequences of its use. The 3T s Formulary NHS Swindon, NHS Wiltshire Great Western Hospitals NHS Foundation Trust (In collaboration with Avon and Wiltshire Mental Health Partnership and Oxford Health NHS Foundation Trust) Shared

More information

Consultation Group: Lead Community Dietitians Aberdeen, Aberdeenshire and Moray CHP. Review Date: October Uncontrolled when printed.

Consultation Group: Lead Community Dietitians Aberdeen, Aberdeenshire and Moray CHP. Review Date: October Uncontrolled when printed. Policy For The Prescribing and Administration Of Oral Nutritional Supplements In Adults By General Practitioners And Primary Care Staff Working Within NHS Grampian Co-ordinators: Dietetic Prescribing Advisor,

More information

Buprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008

Buprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008 Buprenorphine: An Introduction Sharon Stancliff, MD Harm Reduction Coalition September 2008 Objective Participants will be able to: Discuss the role of opioid maintenance in reducing morbidity and mortality

More information

Prescribing Framework for Naltrexone in Alcohol Relapse Prevention

Prescribing Framework for Naltrexone in Alcohol Relapse Prevention Prescribing Framework for Naltrexone in Alcohol Relapse Prevention Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker) GP s Name:... Communication We agree to treat this patient

More information

Methadone Maintenance

Methadone Maintenance Methadone Maintenance A Practical Guide to Pharmacotherapy Methadone/Buprenorphine 101 Workshop, April 1, 2017 Ron Joe, MD, DABAM Objectives I. Pharmacology Of Methadone II. Practical Application of Pharmacology

More information

Opioid Management of Chronic (Non- Cancer) Pain

Opioid Management of Chronic (Non- Cancer) Pain Optima Health Opioid Management of Chronic (Non- Cancer) Pain Guideline History Original Approve Date 5/08 Review/Revise Dates 11/09, 9/11, 9/13, 09/15, 9/17 Next Review Date 9/19 These Guidelines are

More information

Opioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018

Opioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Opioid Step Policy Page: 1 of 6 Last Review Date: March 16, 2018 Opioid Step Policy Description

More information

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States

More information

2004-L SEPTEMBER

2004-L SEPTEMBER BULLETIN INTELLIGENCE Buprenorphine: Potential for Abuse Product No. 2004-L0424-013 SEPTEMBER 2004 U. S. D E P A R T M E N T O F J U S T I C E NDIC Within the past 2 years buprenorphine a Schedule III

More information

NHSG/Pol/OralNut/MGPG639

NHSG/Pol/OralNut/MGPG639 Title: Identifier: Policy And Procedure For General Practitioners And Primary Care Staff For Managing Malnutrition And Prescribing Oral Nutritional Supplements In Adults NHSG/Pol/OralNut/MGPG639 Replaces:

More information

POLICY DOCUMENT. CG/pain management in opioid dependency/03/15. Associate Director of Pharmacy

POLICY DOCUMENT. CG/pain management in opioid dependency/03/15. Associate Director of Pharmacy POLICY DOCUMENT Document Title Reference Number PRESCRIBING FOR PAIN MANAGEMENT IN OPIOID DEPENDENT CLIENTS CG/pain management in opioid dependency/03/15 Policy Type Clinical Guideline Electronic File/Location

More information

Summary of Recommendations...3. PEG: A Three-Item Scale Assessing Pain (Appendix A) Chronic Pain Flow Sheet Acute Pain Flow Sheet...

Summary of Recommendations...3. PEG: A Three-Item Scale Assessing Pain (Appendix A) Chronic Pain Flow Sheet Acute Pain Flow Sheet... Table of Contents Summary of Recommendations....3 PEG: A Three-Item Scale Assessing Pain (Appendix A)...12 Chronic Pain Flow Sheet...13 Acute Pain Flow Sheet...14 Pocket Guide: Tapering Opioids for Chronic

More information

NHS Grampian Staff Guidance For The Management Of Hypomagnesaemia In Adults. Consultation Group: See Page 4. Review Date: June 2021

NHS Grampian Staff Guidance For The Management Of Hypomagnesaemia In Adults. Consultation Group: See Page 4. Review Date: June 2021 NHS...... Grampian NHS Grampian Staff Guidance For The Management Of Hypomagnesaemia In Adults Co-ordinators: Consultation Group: Approver:. Senior Medicines Information Pharmacist See Page 4 Medicine

More information

NHS Grampian Staff Guidance For The Management Of Hypomagnesaemia In Adults

NHS Grampian Staff Guidance For The Management Of Hypomagnesaemia In Adults NHS Grampian Staff Guidance For The Management Of Hypomagnesaemia In Adults Co-ordinators: Sarah Gethings Medicine Information Pharmacist Consultation Group: See Page 4 Approver: Medicine Guidelines and

More information

SHARED CARE PROTOCOL CHOLINESTERASE INHIBITORS IN ALZHEIMER S DEMENTIA

SHARED CARE PROTOCOL CHOLINESTERASE INHIBITORS IN ALZHEIMER S DEMENTIA SHARED CARE PROTOCOL CHOLINESTERASE INHIBITORS IN ALZHEIMER S DEMENTIA Introduction Alzheimer s disease is the most common cause of dementia. It is characterised by an insidious onset of global mental

More information

C AT E G O R Y I I I COMMUNICATION, TREATMENT & PREVENTION INTERVENTIONS PHARMACOLOGY OF ADDICTIONS

C AT E G O R Y I I I COMMUNICATION, TREATMENT & PREVENTION INTERVENTIONS PHARMACOLOGY OF ADDICTIONS C AT E G O R Y I I I COMMUNICATION, TREATMENT & PREVENTION INTERVENTIONS PHARMACOLOGY OF ADDICTIONS 1.0 Introduction Medications are used in the treatment of drug, alcohol and nicotine dependence to manage

More information

Initiation of Clozapine Treatment Community Patients

Initiation of Clozapine Treatment Community Patients Initiation of Clozapine Treatment Community Patients Who Should Read This Policy Target Audience All clinical staff working in the community N/A N/A Initiation of Clozapine Treatment for Patients in the

More information

An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT

An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT Goals of Discussion Recognize opioid use disorder (OUD) Discuss the pharmacology of medication assisted treatments (MAT)

More information

Dear DEA. Howard A. Heit, MD, FACP, FASAM,* Edward Covington, MD, and Patricia M. Good

Dear DEA. Howard A. Heit, MD, FACP, FASAM,* Edward Covington, MD, and Patricia M. Good PAIN MEDICINE Volume 5 Number 3 2004,* Edward Covington, MD, and Patricia M. Good *Georgetown University, Washington, District of Columbia; Cleveland Clinic Foundation, Cleveland, Ohio; Office of Diversion

More information

Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services

Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services VIOLENCE, AGGRESSION OR SEVERE BEHAVIOURAL DISTURBANCE Introduction During an acute episode or illness, some

More information

Prescribing Framework for Galantamine in the Treatment and Management of Dementia

Prescribing Framework for Galantamine in the Treatment and Management of Dementia Hull & East Riding Prescribing Committee Prescribing Framework for Galantamine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)

More information

Substance use and misuse

Substance use and misuse An open learning programme for pharmacists and pharmacy technicians Substance use and misuse Educational solutions for the NHS pharmacy workforce DLP 160 Contents iii About CPPE open learning programmes

More information

Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia

Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia Hull & East Riding Prescribing Committee Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)

More information

GOALS AND OBJECTIVES

GOALS AND OBJECTIVES SUBOXONE AND VIVITROL: ARE THERE DISPARITIES SURFACING IN MEDICATION ASSISTED TREATMENTS? P R E S E N T E D B Y D R. K I AM E M AH A N I A H & D R. M Y E C H I A M I N T E R - J O R D AN GOALS AND OBJECTIVES

More information

SHARED CARE AGREEMENT: MELATONIN (CHILDREN)

SHARED CARE AGREEMENT: MELATONIN (CHILDREN) NB: This document should be read in conjunction with the current Summary of Product Characteristics (SPC) where appropriate. DRUG AND INDICATION: Generic drug name: Formulations: MELATONIN 3mg immediate

More information

Probuphine. (buprenorphine implant) New Product Slideshow

Probuphine. (buprenorphine implant) New Product Slideshow Probuphine (buprenorphine implant) New Product Slideshow Introduction Brand name: Probuphine Generic name: Buprenorphine Pharmacological class: Opioid (partial agonist-antagonist) Strength and Formulation:

More information

Brief History of Methadone Maintenance Treatment

Brief History of Methadone Maintenance Treatment METHADONE Brief History of Methadone Maintenance Treatment Methadone maintenance treatment was on the cusp of the social revolution in the sixties. Doctors and public health workers had concluded what

More information

Document Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml

Document Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Title Document Details Patient Group Direction (PGD) Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Trust Ref No 1445-36348 Local Ref (optional) Main points the document The treatment of

More information

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE SHARED CARE AGREEMENT

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE SHARED CARE AGREEMENT DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE SHARED CARE AGREEMENT NALTREXONE 50mg TABLETS For Opioid Relapse Prevention (in formerly opioid dependent patients) This shared care agreement is aimed at all

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 19 December 2007

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 19 December 2007 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 December 2007 METHADONE AP-HP 1mg, gelatin-coated capsule Box of 7 (CIP: 379 146-2) METHADONE AP-HP 5mg, gelatin-coated

More information

Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction

Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary

More information

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE SHARED CARE AGREEMENT. METHADONE ORAL SOLUTION 1mg/ml

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE SHARED CARE AGREEMENT. METHADONE ORAL SOLUTION 1mg/ml DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE SHARED CARE AGREEMENT METHADONE ORAL SOLUTION 1mg/ml This shared care agreement is aimed at all prescribers within the Local Enhanced Service (LES) and General

More information

Essential Shared Care Agreement Naltrexone

Essential Shared Care Agreement Naltrexone In partnership with as part of Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. The patient s GP 2. Put one copy

More information

NHS Grampian Staff Guideline For The Management Of Acute Hypophosphataemia In Adults

NHS Grampian Staff Guideline For The Management Of Acute Hypophosphataemia In Adults NHS Grampian Staff Guideline For The Management Of Acute Hypophosphataemia In Adults Co-ordinators: Medicine Information Pharmacist Consultation Group: See Page 5 Approver: Medicine Guidelines and Policies

More information

Consultation Group: See relevant page in the PGD. Review Date: October 2017

Consultation Group: See relevant page in the PGD. Review Date: October 2017 Patient Group Direction For Supply Of Paracetamol Oral Suspension 120mg/5mL For Prevention Of Post Immunisation Fever Following Administration Of Meningococcal Group B Vaccine (Bexsero ) By Community Pharmacists

More information

NHS Grampian Staff Guideline for the Management of Acute Hypokalaemia in Adults

NHS Grampian Staff Guideline for the Management of Acute Hypokalaemia in Adults NHS Grampian Staff Guideline for the Management of Acute Hypokalaemia in Adults Co-ordinators: Medicines Information Pharmacist Consultation Group: See relevant page in guidance Approver: Medicine Guidelines

More information

SHARED CARE GUIDELINE FOR BUCCAL MIDAZOLAM FOR THE TREATMENT OF PROLONGED SEIZURES IN CHILDREN

SHARED CARE GUIDELINE FOR BUCCAL MIDAZOLAM FOR THE TREATMENT OF PROLONGED SEIZURES IN CHILDREN SHARED CARE GUIDELINE FOR BUCCAL MIDAZOLAM FOR THE TREATMENT OF PROLONGED SEIZURES IN CHILDREN 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical, nursing and pharmacy staff in the

More information

Job Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014

Job Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014 PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN FORTH VALLEY Protocol Number 445 Version 1 Date protocol prepared: June 2014 Date protocol due

More information

New Zealand Clinical Guidelines for the Use of Buprenorphine (with or without Naloxone) in the Treatment of Opioid Dependence

New Zealand Clinical Guidelines for the Use of Buprenorphine (with or without Naloxone) in the Treatment of Opioid Dependence New Zealand Clinical Guidelines for the Use of Buprenorphine (with or without Naloxone) in the Treatment of Opioid Dependence Citation: Ministry of Health. 2010. New Zealand Clinical Guidelines for the

More information

Opiate Use Disorder and Opiate Overdose

Opiate Use Disorder and Opiate Overdose Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5

More information

Consultation Group: See page 7. Review Date: June Uncontrolled when printed. Version 1. Executive Sign-Off

Consultation Group: See page 7. Review Date: June Uncontrolled when printed. Version 1. Executive Sign-Off Guidance For Drug Treatment Services In Grampian Undertaking Supply Of Naloxone To People At Risk Of Opioid Overdose, Significant Others And Services In Contact With Those At Risk Co-ordinators: Specialist

More information

FENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA

FENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA FENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAMES: HICL = H3AT Fentanyl citrate transmucosal Actiq (fentanyl citrate) lozenge on a handle 200, 400, 600, 800,

More information

This letter authorises the extended use of the following protocol until 1st September 2018:

This letter authorises the extended use of the following protocol until 1st September 2018: NHS Grampian Westholme Woodend Hospital Queens Road ABERDEEN AB15 6LS NHS Grampian Date: 22nd March 2018 Our Ref: FA/NRTComm/MGPG/Mar18 Enquiries to: Frances Adamson Extension: 56689 Direct Line: 01224

More information

Neonatal Abstinence Syndrome Questions & Answers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012)

Neonatal Abstinence Syndrome Questions & Answers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012) Neonatal bstinence Syndrome Questions & nswers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012) For more information and to download a copy of the NS Clinical Practice Guidelines, please visit

More information

Citation: Ministry of Health Practice Guidelines for Opioid Substitution Treatment in New Zealand Wellington: Ministry of Health.

Citation: Ministry of Health Practice Guidelines for Opioid Substitution Treatment in New Zealand Wellington: Ministry of Health. Practice Guidelines for Opioid Substitution Treatment in New Zealand 2008 Practice Guidelines for Opioid Substitution Treatment in New Zealand 2008 Citation: Ministry of Health. 2008. Practice Guidelines

More information

for adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services

for adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services The supply of Champix (Varenicline) Tablets 500mcg and 1mg by registered community pharmacists for smoking cessation / management of nicotine withdrawal for adults engaged with the Family Wellbeing Service

More information

Bournemouth, Dorset and Poole Prescribing Forum

Bournemouth, Dorset and Poole Prescribing Forum SHARED CARE GUIDELINE FOR THE USE OF ATOMOXETINE IN ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER INDICATION Atomoxetine is a non-stimulant non-amphetamine inhibitor of noradrenaline reuptake. It

More information

(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)

(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Buprenorphine Initiation and Maintenance in Pregnancy (Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Assessment The diagnosis of OUD should be confirmed by DSM-5

More information

Prepublication Requirements

Prepublication Requirements Issued Prepublication Requirements The Joint Commission has approved the following revisions for prepublication. While revised requirements are published in the semiannual updates to the print manuals

More information

Effective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go )

Effective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go ) Effective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go ) This shared care agreement outlines the ways in which the responsibilities

More information

Controlled Document Number: Version Number: 1. Controlled Document Sponsor: Controlled Document Lead (Author): On: July Review Date: July 2020

Controlled Document Number: Version Number: 1. Controlled Document Sponsor: Controlled Document Lead (Author): On: July Review Date: July 2020 Guidelines for the Use of Naloxone in Palliative Care in Adult Patients CONTROLLED DOCUMENT CATEGORY: CLASSIFICATION: Controlled Document Number: Version Number: 1 Controlled Document Sponsor: Controlled

More information

Suboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets

Suboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.32 Subject: Suboxone Drug Class Page: 1 of 7 Last Review Date: June 24, 2016 Suboxone Drug Class Description

More information

Peterborough Nalmefene Pathway Responsibilities for Specialist Services & GP

Peterborough Nalmefene Pathway Responsibilities for Specialist Services & GP Peterborough Nalmefene Pathway Responsibilities for Specialist Services & GP INTRODUCTION/BACKGROUND In November 2014 NICE (National Institute of Clinical Excellence) published the Technology Appraisal

More information

NHS FORTH VALLEY LOCAL ENHANCED SERVICE (2010) General Practitioner Prescribing Service (GPPS) Opiate Assisted Treatment Service Specification

NHS FORTH VALLEY LOCAL ENHANCED SERVICE (2010) General Practitioner Prescribing Service (GPPS) Opiate Assisted Treatment Service Specification NHS FORTH VALLEY LOCAL ENHANCED SERVICE (2010) Rationale General Practitioner Prescribing Service (GPPS) Opiate Assisted Treatment Service Specification Aims It is the responsibility of general practitioners

More information

ESCA: Cinacalcet (Mimpara )

ESCA: Cinacalcet (Mimpara ) ESCA: Cinacalcet (Mimpara ) Effective Shared Care Agreement for the Treatment of Primary hyperparathyroidism when parathyroidectomy is contraindicated or not clinically appropriate. Specialist details

More information

Building capacity for a CHC response to Ontario's Opioid Crisis

Building capacity for a CHC response to Ontario's Opioid Crisis Building capacity for a CHC response to Ontario's Opioid Crisis Rob Boyd Oasis Program Director Luc Cormier, RN, MScN Community Health Nurse Sandy Hill Community Health Centre #AOHC2016 @rboyd6 @SandyHillCHC

More information

The CARA & Buprenorphine Prescribing for APNs & PAs

The CARA & Buprenorphine Prescribing for APNs & PAs The CARA & Buprenorphine Prescribing for APNs & PAs William J. Lorman, JD, PhD, MSN, PMHNP-BC, CARN-AP FIAAN Assistant Clinical Professor, Drexel University, Philadelphia, PA V. P. & Chief Clinical Officer,

More information